- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07690657
Evaluating Intervention Allocation Policies for Reducing Hospital Readmissions at Michigan Medicine
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
The intervention affects only how the TOC bundle is assigned and does not alter how the telephone calls are delivered. For example, both care navigators and pharmacists receive the same patient information and follow the same call procedures before and after the intervention.
Individuals with predicted benefits greater than the 40% quantile are assigned the phone call bundle while others were not assigned the bundle. During the trial the 40% quantile will be dynamically determined using discharge data from the previous week.
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Stephanie Shepard, PhD
- Telefonnummer: 734-647-1098
- E-Mail: sdokeefe@umich.edu
Studienorte
-
-
Michigan
-
Ann Arbor, Michigan, Vereinigte Staaten, 48109
- The University of Michigan
-
Kontakt:
- Stephanie Shepard, PhD
- Telefonnummer: 734-647-1098
- E-Mail: sdokeefe@umich.edu
-
Hauptermittler:
- Jenna Wiens, PhD
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- Patient meets the primary care established rule at Michigan Medicine (MM), AND
- Patient's primary care physician (PCP) Department is one of our General Medicine or Family Medicine or Medical-Pediatrics departments, AND
- Inpatient class is Inpatient or Observation or Obs Greater than 48 hours or Outpatient in a Bed or Extended Recovery or Hospital Care at Home Inpatient or Hospital Care at Home Observation, AND
- Discharged from General Medicine or Family Medicine or Medicine Observation services, AND
- Disposition of home or home with home care
Exclusion Criteria:
- Physician Organization of Michigan Accountable Care Organization (POM ACO)
- Sepsis patients (had a diagnosis of sepsis during admission, active or resolved on the hospital problem list)
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Verdreifachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Aktiver Komparator: Control Arm/Standard of care
The Control Arm, in which patients with a LACE Index score of 9 or greater on the day of hospital discharge will receive TOC interventions.
This is the currently implemented allocation policy at Michigan Medicine.
In this setting, approximately 60% of patients receive the TOC intervention.
Thus, we will use a threshold of the 40th percentile for assigning the TOC telephone call bundle.
Note that to maintain the 60% intervention rate throughout the study, the score threshold (LACE 9 or greater) will be monitored and dynamically adjusted.
The LACE Index has four components: Length of Stay (L), Acuity of the Admission (A), Comorbidities (C), and Emergency Department Visits (E), and estimates the risk of a patient having an unplanned hospital readmission after being discharged from their current encounter.
|
The LACE Index has four components: Length of Stay (L), Acuity of the Admission (A), Comorbidities (C), and Emergency Department Visits (E), and estimates the risk of a patient having an unplanned hospital readmission after being discharged from their current encounter.
|
|
Experimental: Experimental Arm
The Experimental Arm, in which Causal-Hospital reAdmission Risk Prediction Model (C-HARP) scores will be used to allocate TOC interventions.
C-HARP is a machine learning model that leverages routinely collected and stored patient data in the electronic health record (EHR) to estimate how much a patient will benefit from receiving MM's TOC telephone call bundle.
The assignment threshold will be defined as the 40th percentile of C-HARP scores within the most recent 100 days of the target cohort, so that approximately 60% of patients are assigned the telephone call bundle.
Based on current retrospective data, this threshold corresponds to a C-HARP score of 18.
|
The Experimental Arm will allocate TOC interventions based on scores generated by the Causal-Hospital reAdmission Risk Prediction Model (C-HARP), C-HARP is a linear model that leverages routinely collected and stored patient data in the electronic health record (EHR) to estimate how much a patient will benefit from receiving Michigan Medicine's (MM's) TOC telephone call bundle.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
The number of 30-day all-cause unplanned readmission or death
Zeitfenster: 30 calendar days following the index discharge
|
An unplanned readmission is defined as any not canceled inpatient, outpatient, or observation hospital admission with an admission type not recorded as "scheduled."
Deaths are determined using the Michigan Death Index and matched to patient records using Social Security numbers.
|
30 calendar days following the index discharge
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
The number of 90-day all-cause unplanned readmission or death
Zeitfenster: 90 calendar days following the index discharge
|
An unplanned readmission is defined as any not canceled inpatient, outpatient, or observation hospital admission with an admission type not recorded as "scheduled."
Deaths are determined using the Michigan Death Index and matched to patient records using Social Security numbers.
|
90 calendar days following the index discharge
|
|
Time to first 90-day all-cause unplanned readmission or death
Zeitfenster: 90 calendar days following the index discharge
|
An unplanned readmission is defined as any not canceled inpatient, outpatient, or observation hospital admission with an admission type not recorded as "scheduled."
Deaths are determined using the Michigan Death Index and matched to patient records using Social Security numbers.
|
90 calendar days following the index discharge
|
|
TOC telephone call bundle completion (care navigator call)
Zeitfenster: 5 calendar days after discharge.
|
A care navigator call is considered complete if a completed call record is observed within 5 calendar days after discharge. Calls are considered incomplete if the corresponding completed call record occurs after an all-cause unplanned readmission. |
5 calendar days after discharge.
|
|
TOC telephone call bundle completion (clinical pharmacist call)
Zeitfenster: 14 calendar days after discharge
|
A clinical pharmacist call is considered complete if a completed call record is observed within 14 calendar days after discharge. Calls are considered incomplete if the corresponding completed call record occurs after an all-cause unplanned readmission. |
14 calendar days after discharge
|
|
TOC telephone call bundle completion (both calls)
Zeitfenster: 14 calendar days after discharge
|
Completed the care navigator call and completed the clinical pharmacist call. Calls are considered incomplete if the corresponding completed call record occurs after an all-cause unplanned readmission. |
14 calendar days after discharge
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienstuhl: Jenna Wiens, PhD, University of Michigan
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- HUM00282075
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Übergang der Pflege
-
Rigshospitalet, DenmarkThe Augustinus Foundation, Denmark.AbgeschlossenNahinfrarotspektroskopie, Transition, KaiserschnittDänemark
-
The Affiliated Hospital of Xuzhou Medical UniversityRekrutierungCLL | SLL | CAR-T-ZelltherapieChina
-
Xuzhou Medical UniversityNoch keine RekrutierungNicht-invasive CAR-T-Zellüberwachung | BCMA-gerichtete PET-Bildgebung | CAR-T-Zell-Biodistribution und -Persistenz | GMP-konforme Radiopharmazeutische Zubereitung
-
Duke UniversityNational Institutes of Health (NIH)RekrutierungTransplantation hämatopoetischer Stammzellen | CAR-T-ZelltherapieVereinigte Staaten
-
National Taiwan University HospitalNoch keine Rekrutierung
-
Imperial College LondonAbgeschlossenProof of Concept -StudieVereinigtes Königreich
-
University of RegensburgAbgeschlossenTrain-of-Four-MonitoringDeutschland
-
Research Unit Of General Practice, CopenhagenUniversity of Copenhagen; Region Capital Denmark; The Copenhagen General Practice... und andere MitarbeiterAbgeschlossen
-
Aalborg UniversityThe General Practice Foundation in Denmark (grant number A3495); The Novo Nordisk... und andere MitarbeiterAbgeschlossenPoint-of-Care-UltraschallDänemark
-
Kecioren Education and Training HospitalAbgeschlossenPoint-of-Care-SystemeTruthahn
Klinische Studien zur The LACE Index TOC assignment
-
Buddhist Tzu Chi General HospitalAbgeschlossen
-
I.M. Sechenov First Moscow State Medical UniversityAbgeschlossenTiefe Sedierung | Moderate SedierungRussische Föderation
-
Jaeb Center for Health ResearchAktiv, nicht rekrutierendMukoviszidoseVereinigte Staaten